PARP inhibitors: Clinical utility and possibilities of overcoming resistance
Author:
Funder
NIH/NCI
Publisher
Elsevier BV
Subject
Obstetrics and Gynecology,Oncology
Reference67 articles.
1. Integrated genomic analyses of ovarian carcinoma
2. DNA end resection, homologous recombination and DNA damage checkpoint activation require CDK1;Ira;Nature,2004
3. Repair of strand breaks by homologous recombination;Jasin;Cold Spring Harb. Perspect. Biol.,2013
4. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer;Konstantinopoulos;Cancer Discov.,2015
5. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy;Farmer;Nature,2005
Cited by 166 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. HTS discovery of PARP1-HPF1 complex inhibitors in cancer;SLAS Discovery;2023-12
2. A PARP14/TARG1-Regulated RACK1 MARylation Cycle Drives Stress Granule Dynamics in Ovarian Cancer Cells;2023-10-14
3. Maturation of small nucleolar RNAs: from production to function;RNA Biology;2023-10-05
4. A Review on Poly (ADP-ribose) Polymerase (PARP) - An Enzyme that Share the ability to Catalyze the Transfer of ADP-Ribose to Target Proteins;Asian Journal of Pharmacy and Technology;2023-08-26
5. Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinoma;Molecular Carcinogenesis;2023-07-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3